






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : C07D 401/04, A61K 31/41, 31/44, 31/495, C07D 249/12	A1	(11) International Publication Number: WO 96/01818 (43) International Publication Date: 25 January 1996 (25.01.96)
(21) International Application Number: PCT/EP95/02619 (22) International Filing Date: 5 July 1995 (05.07.95) (30) Priority Data: 94202015.7 12 July 1994 (12.07.94) EP <i>(34) Countries for which the regional or international application was filed:</i> AT et al. (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): HEERES, Jan [NL/BE]; Leemskuilen 18, B-2350 Vosselaar (BE). STOKBROECKX, Raymond, Antoine [BE/BE]; Rode Kruisstraat 17, B-2340 Beerse (BE). MOSTMANS, Joseph, Hector [BE/BE]; Breughelstraat 28 bus 3, B-2018 Antwerpen (BE). VAN DER VEKEN, Louis, Jozef, Elisabeth [BE/BE]; Oudebaan 48, B-2350 Vosselaar (BE).	(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i>	

(54) Title: SULFONAMIDE DERIVATIVES OF AZOLONES ANTI-HELICOBACTER AGENTS


(1)




(a-1)




(a-2)




(a-3)




(a-4)



(a-5)



(a-6)



(a-7)

(57) Abstract

The invention is concerned with the compounds having formula (I) the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Y is CH or N; R¹, R² and R³ each independently are hydrogen or C₁₋₄alkyl; R⁴ and R⁵ each independently are hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxy, trifluoromethyl, trifluoromethyloxy or difluoromethyloxy; R⁶ is C₁₋₄alkyl; or phenyl optionally substituted with halo, C₁₋₄alkylcarbonylamino, C₁₋₄alkyloxy, C₁₋₄alkyl or nitro; Z is C=O or CHOH; and (1) is a radical of formula ((a-1), (a-2), (a-3), (a-4), (a-5), (a-6), or (a-7). Compositions comprising said compounds, processes for preparing the same and the use of these compounds as a medicine.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

SULFONAMIDE DERIVATIVES OF AZOLONES ANTI-HELICOBACTER AGENTS


The present invention is concerned with substituted azolone derivatives which are potent anti-*Helicobacter* agents.

US-4,791,111 discloses azolones having a structure similar to that of the present compounds and which are intermediates in the preparation of [[4-[4-(4-phenyl-1-piperazinyl)phenoxy]methyl]-1,3-dioxolan-2-yl]methyl]-1*H*-imidazoles and -1*H*-1,2,4-triazoles.

In US-4,931,444 are described substituted azolone derivatives having 5-lipoxygenase inhibiting activity. The present compounds are distinguished therefrom by their useful anti-*Helicobacter* activity.

In the eradication of *Helicobacter*, dual therapies comprising the separate administration of two antibiotic drugs have not been satisfactory because of one or more of the following reasons: a low eradication rate, numerous side effects and development of resistance by *Helicobacter*. Triple therapies comprising the administration of two antibiotics and a bismuth compound have been shown to be effective, but are very demanding for the patients and are also compromised by side effects. The present compounds show the advantage that they may be used in a monotherapy in the eradication of *Helicobacter pylori* and related species.


The present invention is concerned with compounds having the formula










the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

- Y is CH or N;
 R^1 , R^2 and R^3 each independently are hydrogen or C_{1-4} alkyl;
 R^4 and R^5 each independently are hydrogen, halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, trifluoromethyl, trifluoromethyloxy or difluoromethyloxy;
 R^6 is C_{1-4} alkyl; or phenyl optionally substituted with halo, C_{1-4} alkylcarbonylamino, C_{1-4} alkyloxy, C_{1-4} alkyl or nitro;
 Z is C=O or CHO; and

-2-

 is a radical of formula



As used in the foregoing definitions halo defines fluoro, chloro, bromo and iodo;

- 5 C₁₋₄alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms: methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl. C₁₋₆alkyl defines C₁₋₄alkyl radicals as defined hereinbefore and the higher homologs thereof having from 5 to 6 carbon atoms such as, for example, pentyl and hexyl.

10

- The term pharmaceutically acceptable addition salt as used hereinbefore defines the non-toxic, therapeutically active addition salt forms which the compounds of formula (I) may form. The compounds of formula (I) having basic properties may be converted into the corresponding therapeutically active, non-toxic acid addition salt forms by treating the free base form with a suitable amount of an appropriate acid following conventional procedures. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methane-sulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids. The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

25

- The term stereochemically isomeric forms as used hereinbefore defines the different isomeric as well as conformational forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically and conformationally isomeric forms, said mixtures containing all diastereomers, enantiomers and/or

30


-3-

conformers of the basic molecular structure. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.

5 The absolute configuration of each chiral center may be indicated by the stereochemical descriptors R and S. For the compounds having two chiral centers, the relative stereodescriptors R* and S* are used in accordance with the Chemical Abstracts rules (Chemical Substance Name Selection Manual (CA), 1982 Edition, Vol. III, Chapter 20).

10 Some compounds of the present invention may exist in different tautomeric forms and all such tautomeric forms are intended to be included within the scope of the present invention.

15 A first group of interesting compounds are those compounds of formula (I) wherein R⁴ is halo and R⁵ is hydrogen.

A second group of interesting compounds are those compounds of formula (I) wherein  is a radical of formula (a-1) or (a-2).


20 A third group of interesting compounds are those compounds of formula (I) wherein Y is N and R¹ is hydrogen.

A fourth group of interesting compounds are those compounds of formula (I) wherein R² is C₁₋₄alkyl and R³ is hydrogen.

25 A fifth group of interesting compounds are those compounds of formula (I) wherein R⁶ is C₁₋₄alkyl.

30 Preferred compounds are those compounds of formula (I) wherein R¹, R³ and R⁵ are hydrogen; R² is C₁₋₄alkyl; R⁴ is halo; and Y is N.

More preferred compounds are those compounds of formula (I) wherein R¹, R³ and R⁵ are hydrogen; R² is ethyl; R⁴ is halo; Y is N; R⁶ is C₁₋₄alkyl; and


 is a radical of formula (a-1) or (a-2).

35 The most preferred compound is 1-[5-[2-[1-[(4-chlorophenyl)hydroxymethyl]propyl]-2,3-dihydro-3-oxo-4H-1,2,4-triazol-4-yl]-2-pyridinyl]-4-(methylsulfonyl)piperazine, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.

-4-


Analogous procedures for the preparation of compounds such as the present compounds of formula (I) have been described in US-4,791,111 and US-4,931,444.

- 5 In particular, the compounds of formula (I) can be prepared by the reaction of an intermediate of formula (II) with a reagent of formula (III), in a reaction-inert solvent, e.g. dichloromethane, *N,N*-dimethylformamide and the like, optionally in the presence of a base, e.g. triethylamine.



10

Alternatively, the compounds of formula (I) can be prepared by *N*-alkylating an intermediate of formula (V) with a reagent of formula (VI) in an appropriate solvent and in the presence of a suitable base.



15

The compounds of formula (I) can also be converted into each other following art-known procedures of functional group transformation.

- 20 For example, the compounds of formula (I) wherein Z represents C=O can be converted into the compounds of formula (I) wherein Z represents CHOH following art-known reductions. For example, said reduction can conveniently be conducted by reaction with a metal hydride or complex metal hydride, e.g. sodium borohydride, sodium cyanoborohydride and the like in water, 1-methyl-pyrrolidinone, acetonitrile, an alcoholic medium,
- 25 e.g. methanol, ethanol, or an ether, e.g. tetrahydrofuran, 1,4-dioxane; or in a mixture of such solvents.

Alternatively, said reduction can be conducted by reaction with tris(1-methylethoxy)-potassium hydroborate, tris(1-methylpropyl)sodium hydroborate or tris(1-methylpropyl)potassium hydroborate in a reaction-inert solvent, e.g. tetrahydrofuran or

-5-

N,N-dimethylformamide.

Optionally, the reaction of the intermediate of formula (II) with the reagent of formula (III) and the reduction reaction described above may be conducted in a single reaction vessel.

5


Finally, pure isomeric forms of the compounds of formula (I) can be separated from the mixture by conventional separation methods. In particular, the enantiomers may be separated by column chromatography using a chiral stationary phase such as a suitably derivatized cellulose, for example, tri(dimethylcarbamoyl)cellulose (Chiralcel OD®) and similar chiral stationary phases.

10

In all foregoing and in the following preparations, the reaction products may be isolated from the reaction mixture and, if necessary, further purified according to methodologies generally known in the art.

15

The intermediates of formula (II) may be prepared by the reaction of a compound of formula (IV) with an acid, e.g. hydrobromic acid and the like.



20

The intermediates of formula (V) may be prepared following the procedures as described hereinabove for the preparation of the compounds of formula (I) from the intermediates of formula (II).

25

The compounds of formula (I), the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof display useful pharmacological activity against *Helicobacter* species; e.g. *Helicobacter pylori*, *Helicobacter mustelae*, *Helicobacter felis* and the like, in particular *Helicobacter pylori*.

30

Particularly important in this context is the finding that the subject compounds show inhibitory activity against the growth of *Helicobacter* as well as bactericidal activity against said bacteria. The bactericidal effect on *Helicobacter* was determined with

-6-

suspension cultures by means of a procedure described in Antimicrob. Agents Chemother., 1991, vol. 35, pp. 869-872.

5 An interesting feature of the present compounds relates to their highly specific activity against *Helicobacter*. The compounds of formula (I) were found to show no inhibitory activity against any of the following species : *Campylobacter jejuni*, *Campylobacter coli*, *Campylobacter fetus*, *Campylobacter sputorum*, *Vibrio spp.*, *Staphylococcus aureus* and *Escherichia coli*, tested at concentrations up to 10^{-5} M.

10 An important asset of the present compounds is their sustained activity against *H. pylori* at pH below the neutral pH. Activity at a low pH *in vitro* may indicate that a compound is not adversely affected by the acidic environment of the stomach *in vivo*.

15 Consequently, the subject compounds are considered to be valuable therapeutical drugs for treating warm-blooded animals, particularly humans, suffering from *Helicobacter* related diseases or afflictions. Examples of said diseases or afflictions are gastritis, stomach ulcers, duodenal ulcers and gastric cancer.

20 In view of their useful anti-*Helicobacter* properties, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These
25 pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid
30 carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose
35 solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.

When the pharmaceutical composition takes the form of an aqueous solution, those

-7-

- compounds of formula (I) which display low solubility may be formulated as a salt form, or a co-solvent may be added which is water-miscible and physiologically acceptable, e.g. dimethylsulfoxide and the like, or the compounds of formula (I) may be solubilized with a suitable carrier, e.g. a cyclodextrin (CD) or in particular a cyclodextrin derivative such as the cyclodextrin derivatives described in US-3,459,731, EP-A-149,197 (July 24, 1985), EP-A-197,571 (October 15, 1986), US-4,535,152 or WO 90/12035 (October 18, 1990). Appropriate cyclodextrin derivatives are α -, β -, γ -cyclodextrins or ethers and mixed ethers thereof wherein one or more of the hydroxy groups of the anhydroglucose units of the cyclodextrin are substituted with C₁₋₆alkyl, particularly methyl, ethyl or isopropyl; hydroxyC₁₋₆alkyl, particularly hydroxyethyl, hydroxypropyl or hydroxybutyl; carboxyC₁₋₆alkyl, particularly carboxymethyl or carboxyethyl; C₁₋₆alkyl-carbonyl, particularly acetyl; C₁₋₆alkyloxycarbonylC₁₋₆alkyl or carboxyC₁₋₆alkyl-oxyC₁₋₆alkyl, particularly carboxymethoxypropyl or carboxyethoxypropyl; C₁₋₆alkylcarbonyloxyC₁₋₆alkyl, particularly 2-acetyloxypropyl. Especially noteworthy as complexants and/or solubilizers are β -CD, 2,6-dimethyl- β -CD, 2-hydroxyethyl- β -CD, 2-hydroxyethyl- γ -CD, 2-hydroxypropyl- γ -CD and (2-carboxymethoxy)propyl- β -CD, and in particular 2-hydroxypropyl- β -CD.
- The term mixed ether denotes cyclodextrin derivatives wherein at least two cyclodextrin hydroxy groups are etherified with different groups such as, for example, hydroxypropyl and hydroxyethyl.
- The average molar substitution (M.S.) is used as a measure of the average number of moles of alkoxy units per mole of anhydroglucose. The M.S. value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative. In the cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention the M.S. as determined by mass spectrometry is in the range of 0.125 to 10, in particular of 0.3 to 3, or from 0.3 to 1.5. Preferably the M.S. ranges from about 0.3 to about 0.8, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. M.S. values determined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.
- The average substitution degree (D.S.) refers to the average number of substituted hydroxyls per anhydroglucose unit. The D.S. value can be determined by various analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin derivative. In the cyclodextrin derivatives for use in the compositions according to the present invention

-8-

the D.S. as determined by MS is in the range of 0.125 to 3, in particular of 0.2 to 2 or from 0.2 to 1.5. Preferably the D.S. ranges from about 0.2 to about 0.7, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. D.S. values determined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.

- 5 More particular β - and γ -cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention are partially substituted cyclodextrin derivatives wherein the average degree of alkylation at hydroxyl groups of different positions of the anhydroglucose units is about 0% to 20% for the 3 position, 2% to 70% for the 2 position and about 5% to 90% for the 6 position. Preferably the amount of
10 unsubstituted β - or γ -cyclodextrin is less than 5% of the total cyclodextrin content and in particular is less than 1.5%. Another particularly interesting cyclodextrin derivative is randomly methylated β -cyclodextrin.

- Most preferred cyclodextrin derivatives for use in the present invention are those partially substituted β -cyclodextrin ethers or mixed ethers having hydroxypropyl, hydroxyethyl
15 and in particular 2-hydroxypropyl and/or 2-(1-hydroxypropyl) substituents.

- The most preferred cyclodextrin derivative for use in the compositions of the present invention is hydroxypropyl- β -cyclodextrin having a M.S. in the range of from 0.35 to 0.50 and containing less than 1.5% unsubstituted β -cyclodextrin. M.S. values
20 determined by NMR or IR preferably range from 0.55 to 0.75.

- It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity
25 of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.

- 30 In view of the usefulness of the subject compounds in the treatment of *Helicobacter* related diseases it is evident that the present invention provides a method of treating warm-blooded animals, in particular humans, suffering from *Helicobacter* related diseases, said method comprising the systemic administration of a pharmaceutically effective amount of a compound of formula (I), a pharmaceutically acceptable addition
35 salt thereof or a stereochemically isomeric form thereof, in admixture with a pharmaceutical carrier. In a further aspect of the invention, the subjects compounds are administered for use as a medicine.

-9-

In general it is contemplated that an effective daily amount would be from 0.05 mg/kg to 50 mg/kg body weight, preferably from 0.1 mg/kg to 30 mg/kg body weight and more preferably from 0.5 mg/kg to 10 mg/kg body weight.

It is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective ranges mentioned hereinabove are therefore guidelines only and are not intended to limit the scope or use of the invention to any extent.

Optionally, other active compounds used for the eradication of *Helicobacter* can be administered in combination with the compounds of the present invention. The administration may occur separately (i.e. simultaneously, concurrently or consecutively) or the different drugs may be combined in one dosage form. Suitable compounds for a combination therapy are bismuth compounds, e.g. bismuth subcitrate, bismuth subsalicylate, and the like, antibiotics, e.g. ampicillin, amoxicillin, clarithromycin and the like, H₂-receptor antagonists, e.g. cimetidine, ranitidine and the like, and in particular, proton pump inhibitors, e.g. omeprazole, lansoprazole, pantoprazole and the like. For the compounds cited to be useful for a combination therapy with the compounds of formula (I) an effective daily amount would be from 0.05 mg/kg to 50 mg/kg body weight.

Experimental part

Hereinafter, "DMSO" means dimethyl sulfoxide.


Example 1

a) A mixture of (±)-ethyl 4-[5-[2-[1-(4-chlorobenzoyl)propyl]-2,3-dihydro-3-oxo-4H-1,2,4-triazol-4-yl]-2-pyridinyl]-1-piperazinecarboxylate (24 g) in hydrobromic acid, 48% solution in water (250 ml) was stirred and refluxed overnight. The solvent was evaporated and the residue was dissolved in CH₂Cl₂, neutralized with NH₄OH/H₂O and extracted with CH₂Cl₂. The organic layer was washed with water, dried, filtered and evaporated. A sample (3.5 g) of the residue (total 18 g) was purified by column chromatography over silica gel (eluent : CH₂Cl₂/(CH₃OH/NH₃) 99/1). The pure fractions were collected and evaporated. The residue was dissolved in 2-propanol and crystallized into the hydrochloric acid salt (1:1) in 2-propanol. The precipitate was filtered off, washed with 2-propanol and dried at 150°C. The product was dissolved in 2-propanol. Pyridine was added dropwise until all the product was dissolved and subsequently crystallized. The precipitate was filtered off and dried, yielding 1.7 g (±)-2-[1-(4-chlorobenzoyl)propyl]-2,4-dihydro-4-[6-(1-piperazinyl)-3-pyridinyl]-3H-1,2,4-triazol-3-one monohydrochloride (39.4%); mp. 209.8°C (interm. 1).

-10-

- b) A mixture of benzenesulfonyl chloride (0.044 g) and intermediate 1 (0.1 g) in CH_2Cl_2 (10 ml) and *N,N*-diethylethanamine (1 ml) was stirred at room temperature overnight. The mixture was purified by HPLC over silica gel (eluent : CH_2Cl_2 100 to $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 90/10 over a 20 minutes period and 120ml/min.). The desired fraction
- 5 was collected and evaporated, yielding a solution of 0.119 g (85%) in DMSO (10.5 ml) of ($\pm$)-1-[5-[2-[1-(4-chlorobenzoyl)propyl]-2,3-dihydro-3-oxo-4*H*-1,2,4-triazol-4-yl]-2-pyridinyl]-4-(phenylsulfonyl)piperazine (comp. 1).

In a similar manner were prepared :




Co. No.	R ⁶	A
2	4-methylphenyl	N
3	4-methoxyphenyl	N
4	4-bromophenyl	N
5	4-nitrophenyl	N
6	4-(methylcarbonylamino)phenyl	N
7	methyl	N
8	4-chlorophenyl	N
9	4-fluorophenyl	N
10	phenyl	CH
11	4-methylphenyl	CH
12	4-methoxyphenyl	CH
13	4-bromophenyl	CH
14	4-nitrophenyl	CH
15	4-(methylcarbonylamino)phenyl	CH
16	methyl	CH
17	4-chlorophenyl	CH
18	4-fluorophenyl	CH

Example 2

- N,N*-diethylethanamine (1 ml) and benzenesulfonyl chloride (excess; 0.06 g) were added
- 15 to a solution of intermediate 1 (0.1 g) in *N,N*-dimethylformamide (2 ml). The mixture was stirred for 6 hours at room temperature. $\text{K}[\text{OCH}(\text{CH}_3)_2]_3\text{BH}$ 1M in tetrahydrofuran (1.5 ml) was added and the reaction mixture was stirred overnight at room temperature.

-11-

- Two drops of water were added and stirring was continued for 2 hours. CH₂Cl₂ was added until a total volume of 20 ml was reached. The mixture was centrifuged and filtered. MgSO₄ (spatula tip) was added and the mixture was separated by high-performance liquid chromatography over silica gel (eluent A: CH₂Cl₂; eluent B: CH₂Cl₂/CH₃OH 90/10; from 90% A and 10% B, over a 2-minute period (125 ml/min), to 90% A and 10% B; upgrading, over an 18-minute period (125 ml/min), to 100% B). The pure fractions were collected and the solvent was evaporated, yielding 0.054 g of (±)-(R*,R*)-1-[5-[2-[1-[(4-chlorophenyl)hydroxymethyl]propyl]-2,3-dihydro-3-oxo-4H-1,2,4-triazol-4-yl]-2-pyridinyl]-4-(phenylsulfonyl)piperazine (comp. 19).
- In a similar manner were prepared :



Co. No.	R ⁶	A	physical data
20	4-methylphenyl	N	(R*,R*)
21	4-methoxyphenyl	N	(R*,R*)
22	4-bromophenyl	N	(R*,R*)
23	4-nitrophenyl	N	(R*,R*)
24	4-(methylcarbonylamino)phenyl	N	(R*,R*)
25	methyl	N	(R*,R*)
26	4-chlorophenyl	N	(R*,R*)
27	4-fluorophenyl	N	(R*,R*)
28	phenyl	CH	(R*,R*)
29	4-methylphenyl	CH	(R*,R*)
30	4-methoxyphenyl	CH	(R*,R*)
31	4-bromophenyl	CH	(R*,R*)
32	4-(methylcarbonylamino)phenyl	CH	(R*,R*)
33	methyl	CH	(R*,R*)
34	4-chlorophenyl	CH	(R*,R*)
35	4-fluorophenyl	CH	(R*,R*)

15 Pharmacological example

The anti-*Helicobacter* activity of the subject compounds was assessed by the following *in vitro* test procedure.

Example 3 : Activity of test compounds versus *Helicobacter*

The activity of test compounds against *Helicobacter pylori* was determined against a

-12-

standard set of 5 *H. pylori* strains obtained from clinical material. Minimal inhibitory concentrations (MICs) were determined by measuring the activity of *H. pylori* urease after treatment of growing cultures of the bacteria with the antimicrobial agents.

- 5 The test compounds were dissolved in DMSO at a concentration of 10^{-3} M. A dilution to 10^{-4} M in DMSO was also prepared. 10 μ l volumes of these solutions were pipetted in the wells of Repli-Dishes (@Sterilin). Wells containing DMSO alone were included as controls in each Repli-Dish. Ampicillin ((+)-6-[(2-amino-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.trihydrate)
- 10 and metronidazole (2-methyl-5-nitro-1*H*-imidazol-1-ethanol) were included as reference compounds in each batch of tests. (These compounds were tested at final concentrations of 10^{-5} , 10^{-6} , 10^{-7} and 10^{-8} M). Test plates were stored at 4°C until used.
- The five isolates of *H. pylori* were maintained by subculture on 10% blood agar every 2 or 3 days. The bacteria were grown at 37°C under an atmosphere containing 5%
- 15 oxygen, 10% CO₂ and 85% nitrogen. Suspensions of *Helicobacter pylori* for inoculum were prepared in Brain-heart infusion broth and adjusted to an absorbance of 1.5 ± 0.3 at 530 nm.
- Freshly prepared 10% blood agar held at 45°C was added in 1 ml volumes to the wells of the test plates, thus diluting the test compounds to 10^{-5} and 10^{-6} M. The medium was
- 20 allowed to cool, then 10 μ l volumes of bacterial suspension were pipetted on the agar surface. The plates were incubated for 48 hours at 37°C under the microaerophilic atmosphere described above. To facilitate reading of the plates and to ensure that any growth on the media was truly *H. pylori*, advantage was taken of the highly potent urea activity unique to this species. After the 48 hours of incubation, 1 ml volumes of urease
- 25 broth were gently added to each Repli-Dish well and the plates were incubated at 37°C for 2 hours. 100 μ l samples of fluid from each well were then pipetted into the wells of 96-place microdilution plates. A purple colour was interpreted as growth, yellow-orange as no growth of *H. pylori*. By this means a clear end-point was obtained, from which the inhibitory effects could be determined. All compounds that showed activity at either
- 30 of the two concentrations tested were retested with further dilutions included to establish the MIC and with a broader spectrum of bacterial species as target organisms. Thus far, the MIC value for compound 25 was found to be equal or below 10 μ M.

Composition examples

- 35 "Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I), a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof.

-13-

Example 4 : ORAL DROPS

500 Grams of the A.I. was dissolved in 0.5 l of 2-hydroxypropanoic acid and 1.5 l of the polyethylene glycol at 60~80°C. After cooling to 30~40°C there were added 35 l of polyethylene glycol and the mixture was stirred well. Then a solution of 1750 grams of sodium saccharin in 2.5 l of purified water was added. Upon stirring were added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 l, providing an oral drop solution comprising 10 mg/ml of A.I.. The resulting solution was filled into suitable containers.

Example 5 : CAPSULES

20 Grams of the A.I., 6 grams sodium lauryl sulfate, 56 grams starch, 56 grams lactose, 0.8 grams colloidal silicon dioxide, and 1.2 grams magnesium stearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelatin capsules, comprising each 20 mg of the active ingredient.

Example 6 : FILM-COATED TABLETSPreparation of tablet core

A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams starch was mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone in 200 ml of water. The wet powder mixture was sieved, dried and sieved again. 100 Grams microcrystalline cellulose and 15 grams hydrogenated vegetable oil were added. The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 mg of the active ingredient.

Coating


To a solution of 10 grams methyl cellulose in 75 ml of denaturated ethanol was added a solution of 5 grams of ethyl cellulose in 150 ml of CH₂Cl₂. Then there were added 75 ml of CH₂Cl₂ and 2.5 ml 1,2,3-propanetriol. 10 Grams of polyethylene glycol was molten and dissolved in 75 ml of CH₂Cl₂. The latter solution was added to the former and then there were added 2.5 grams of magnesium octadecanoate, 5 grams of polyvinylpyrrolidone and 30 ml of concentrated colour suspension and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example 7 : SUPPOSITORIES

3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 Grams surfactant and triglycerides q.s. ad 300 grams were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37-38°C to form 100 suppositories each containing 30 mg/ml of the A.I.

Claims

1. A compound having the formula



a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

Y is CH or N;








10 R^1 , R^2 and R^3 each independently are hydrogen or C_{1-4} alkyl;

R^4 and R^5 each independently are hydrogen, halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy, trifluoromethyl, trifluoromethyloxy or difluoromethyloxy;

R^6 is C_{1-4} alkyl; or phenyl optionally substituted with halo, C_{1-4} alkylcarbonylamino, C_{1-4} alkyloxy, C_{1-4} alkyl or nitro;

15 Z is C=O or CHOH; and

—— is a radical of formula



20 2. A compound according to claim 1 wherein

R^1 , R^3 and R^5 are hydrogen;

R^2 is C_{1-4} alkyl;

R^4 is halo; and

Y is N.

25

3. A compound according to claim 2 wherein


R^2 is ethyl;


R^6 is C_{1-4} alkyl; and

-15-


 is a radical of formula (a-1) or (a-2).

4. A compound according to claim 1 wherein said compound is
1-[5-[2-[1-[(4-chlorophenyl)hydroxymethyl]propyl]-2,3-dihydro-3-oxo-4*H*-1,2,4-
5 triazol-4-yl]-2-pyridinyl]-4-(methylsulfonyl)piperazine, a pharmaceutically acceptable
addition salt or a stereochemically isomeric form thereof.
5. A pharmaceutical composition comprising a therapeutically effective amount of a
compound as claimed in any of claims 1 to 4 and a pharmaceutically acceptable
10 carrier.
6. A process of preparing a pharmaceutical composition as claimed in claim 5,
characterized in that a therapeutically effective amount of a compound as claimed in
any of claims 1 to 4 is intimately mixed with a pharmaceutically acceptable carrier.
15
7. A compound as claimed in any of claims 1 to 4 for use as a medicine.
8. A therapeutic combination comprising a compound as claimed in any of claims 1 to
4, a pharmaceutically acceptable bismuth compound and/or a proton pump inhibitor.
20
9. A process for preparing a compound of formula




25 wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , Y, Z and  are as defined in claim 1,
characterized by

a) reacting an intermediate of formula (II) with a reagent of formula (III) in a reaction-inert solvent, optionally in the presence of a base;



-16-

b) *N*-alkylating an intermediate of formula (V) with a reagent of formula (VI) in an appropriate solvent and in the presence of a suitable base;



5

and further if desired, converting the compounds of formula (I) into each other following art-known functional group transformation procedures; converting the compounds of formula (I) into an acid addition salt form by treatment with a pharmaceutically acceptable acid; or conversely, converting the salt form into the free base by treatment with alkali;
 10 and/or preparing stereochemically isomeric forms thereof.

INTERNATIONAL SEARCH REPORT

Internal	Application No
PCT/EP 95/02619	

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D401/04 A61K31/41 A61K31/44 A61K31/495 C07D249/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 117, no. 7, 17 August 1992, Columbus, Ohio, US; abstract no. 66400w, H. RAUTELIN ET AL. 'In vitro activity of antifungal azoles against Helicobacter pylori.' page 455 ;column 1 ; see abstract & EUR. J. CLIN. MICROBIOL. INFECT. DIS., vol.11, no.3, 1992 pages 273 - 274 ---	1-7
A	EP,A,0 228 125 (JANSSEN PHARMACEUTICA N.V.) 8 July 1987 cited in the application see the whole document; in particular page 25, example 19, compound no. 118; and page 10, line 55- page 11, line 6 -----	1-7

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

25 October 1995

Date of mailing of the international search report

- 2. 11. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Fink, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat : Application No

PCT/EP 95/02619

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0228125	08-07-87	AU-B- 593736	15-02-90
		AU-B- 1607688	04-08-88
		AU-B- 589726	19-10-89
		AU-B- 6685386	25-06-87
		DE-A- 3684431	23-04-92
		FI-C- 88505	25-05-93
		HK-A- 46295	07-04-95
		IE-B- 59564	09-03-94
		JP-B- 7049428	31-05-95
		JP-A- 62158275	14-07-87
		NO-B- 175150	30-05-94
		US-A- 4791111	13-12-88
